Kathleen Goin Sells 4,302 Shares of Palvella Therapeutics (NASDAQ:PVLA) Stock

Palvella Therapeutics, Inc. (NASDAQ:PVLA) COO Kathleen Goin sold 4,302 shares of the company’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $152.21, for a total value of $654,807.42. Following the sale, the chief operating officer owned 2,154 shares in the company, valued at approximately $327,860.34. The trade was a 66.64% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kathleen Goin also recently made the following trade(s):

• On Wednesday, June 17th, Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock. The stock was sold at an average price of $110.73, for a total transaction of $476,360.46.

Palvella Therapeutics Trading Down 0.4%

NASDAQ:PVLA opened at $142.04 on Friday. The firm has a fifty day simple moving average of $142.35 and a two-hundred day simple moving average of $124.46. The stock has a market capitalization of $2.05 billion, a price-to-earnings ratio of -29.41 and a beta of -0.17. Palvella Therapeutics, Inc. has a 12 month low of $49.13 and a 12 month high of $161.38.

Palvella Therapeutics (NASDAQ:PVLA) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($1.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.35). Equities analysts predict that Palvella Therapeutics, Inc. will post -6.36 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Palvella Therapeutics

Hedge funds have recently modified their holdings of the business. Millennium Management LLC purchased a new stake in shares of Palvella Therapeutics in the first quarter worth $7,553,000. Goldman Sachs Group Inc. bought a new stake in shares of Palvella Therapeutics during the first quarter valued at approximately $533,000. Geode Capital Management LLC grew its holdings in Palvella Therapeutics by 84.7% during the 2nd quarter. Geode Capital Management LLC now owns 173,986 shares of the company’s stock worth $3,923,000 after acquiring an additional 79,787 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Palvella Therapeutics by 108,066.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock valued at $73,000 after acquiring an additional 3,242 shares during the period. Finally, Rhumbline Advisers bought a new position in shares of Palvella Therapeutics during the 2nd quarter worth approximately $224,000. Institutional investors own 40.11% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have weighed in on PVLA. Weiss Ratings restated a “sell (d-)” rating on shares of Palvella Therapeutics in a research note on Monday, June 29th. Stephens reissued an “overweight” rating and set a $220.00 price objective on shares of Palvella Therapeutics in a report on Thursday, May 21st. HC Wainwright reaffirmed a “buy” rating and issued a $270.00 price target on shares of Palvella Therapeutics in a report on Wednesday, July 22nd. Chardan Capital upgraded shares of Palvella Therapeutics to a “strong-buy” rating in a research report on Tuesday, July 28th. Finally, Canaccord Genuity Group set a $232.00 price target on shares of Palvella Therapeutics in a research note on Wednesday, August 5th. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $209.14.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.